Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  BioNTech SE    BNTX

BIONTECH SE

(BNTX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/16/2020 10/19/2020 10/20/2020 10/21/2020 10/22/2020 Date
94.09(c) 93.92(c) 94.35(c) 87.72(c) 86.36(c) Last
2 792 475 2 800 200 1 872 146 3 384 553 2 205 906 Volume
+4.10% -0.18% +0.46% -7.03% -1.55% Change
More quotes
Financials
Sales 2020 459 M 544 M 544 M
Net income 2020 -116 M -137 M -137 M
Net cash position 2020 1 286 M 1 523 M 1 523 M
P/E ratio 2020 -112x
Yield 2020 -
Sales 2021 2 866 M 3 394 M 3 394 M
Net income 2021 1 406 M 1 665 M 1 665 M
Net cash position 2021 2 455 M 2 908 M 2 908 M
P/E ratio 2021 15,5x
Yield 2021 -
Capitalization 17 629 M 20 893 M 20 877 M
EV / Sales 2020 35,6x
EV / Sales 2021 5,29x
Nbr of Employees 1 400
Free-Float 92,4%
More Financials
Company
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. It develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer... 
More about the company
Notations Surperformance© of BioNTech SE
Trading Rating : Investor Rating :
More Ratings
All news about BIONTECH SE
05:45aPFIZER : How Pfizer Partner BioNTech Became a Leader in Coronavirus Vaccine Race
DJ
12:20aBritain partners with Oxford firm to assess coronavirus vaccine T cell respon..
RE
10/21Ecuador signs COVID-19 vaccine supply deals with pharma companies
RE
10/21Pfizer Sets Up Its 'Biggest Ever' Vaccination Distribution Campaign
DJ
10/19Moderna CEO Expects Covid-19 Vaccine Interim Results in November
DJ
10/19Moderna CEO Expects Covid-19 Vaccine Interim Results in November
DJ
10/16Pfizer says earliest U.S. filing for COVID-19 vaccine would be late November
RE
10/16WALL STREET STOCK EXCHANGE : Dow rises, S&P ekes out gain
RE
10/16Pfizer vaccine hopes lift world stocks; dollar, gold on the defensive
RE
10/16WALL STREET STOCK EXCHANGE : Dow advances, S&P ekes out gain as vaccine timeline..
RE
10/16Wall Street gains on vaccine news, retail sales surprise
RE
10/16EXPLAINER : When will COVID-19 vaccines be generally available in the United Sta..
RE
10/16LONDON STOCK EXCHANGE : FTSE 100 snaps four-day losing streak on vaccine hopes
RE
10/16Pfizer COVID-19 vaccine not ready before Election Day
RE
10/16EUROPE : Vaccine hopes, upbeat earnings power European shares
RE
More news
News in other languages on BIONTECH SE
10/21US-Gesundheitsminister macht Hoffnung auf US-weite Impfung bis April
10/20WDH/Moderna-Chef macht Hoffnung auf US-Notfallzulassung für Corona-Impfung
10/16Deux vaccins pourraient être prêts à être autorisés en novembre aux Etats-Uni..
10/16CORONAVIRUS : 2 vaccins peut-être prêts à être autorisés en novembre aux USA
10/16CORONAVIRUS : Pfizer va demander l'homologation de son vaccin fin novembre
More news
Analyst Recommendations on BIONTECH SE
More recommendations
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 69,03 €
Last Close Price 74,02 €
Spread / Highest target 13,5%
Spread / Average Target -6,75%
Spread / Lowest Target -35,6%
EPS Revisions
Managers
NameTitle
Ugur Sahin Chief Executive Officer
Helmut Jeggle Chairman-Supervisory Board
Sierk Pötting Chief Operating & Financial Officer
Özlem Türeci Chief Medical Officer
Christoph Huber Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
BIONTECH SE158.91%20 893
GILEAD SCIENCES, INC.-7.34%75 487
REGENERON PHARMACEUTICALS52.44%60 234
VERTEX PHARMACEUTICALS-3.46%55 058
WUXI APPTEC CO., LTD.64.60%39 515
BEIGENE, LTD.82.54%27 421